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Abstract
BACKGROUND: Chronic hepatitis B (CHB) is becoming a common liver abnormality worldwide. Thus, a series 
of good management is needed to prevent the progression and complications of hepatitis B infection. Tenofovir 
disoproxil fumarate (TDF) is one of the drugs of choice that’s used for CHB management.
AIM: Limited studies were found regarding the efficacy of tenofovir in dealing with CHB. Hence, the aim of this study 
is to determine the efficacy of TDF administration for 24 weeks in subjects with naïve CHB in Medan, Indonesia.
METHODS: Retrospective study was conducted in Haji Adam Malik Hospital Medan, Indonesia, between January 
and December 2019. Subjects were CHB patients aged 18 years or older and were treated TDF for 24 weeks. 
Demographic, clinical, and CHB disease progression parameters (serum alanine aminotransferase [ALT], hepatitis B 
envelope antigen [HBeAg], and hepatitis B virus deoxyribonucleic acid [HBV DNA]) data were obtained.
RESULTS: One hundred and twenty subjects were obtained and divided into 2 groups: HBeAg positive and HBeAg 
negative. Mean age of subjects was 46.5 ± 10.36 years in HBeAg positive group and 48.6 ± 10.67 years HBeAg 
negative group, with predominant males’ subjects in both groups (58.3% vs. 61.7%, respectively). Serum ALT 
normalization and undetectable serum HBV DNA were observed in more than 70% and 65% of subjects in both 
groups, respectively (both p < 0.001). Serum HBeAg loss was achieved in 10.8% subjects (p < 0.001). No subject 
showed serum HbsAg loss.
CONCLUSION: Our results are consonant with current clinical guidelines and other evidence literature. For both 
HBeAg-positive and HBeAg-negative populations, TDF administration for 24 weeks has good efficacy in naïve CHB 
patients.
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Introduction
Hepatitis B virus, also known as HBV, is a 
double-stranded deoxyribonucleic acid (DNA) virus 
from the hepadnavirus family that causes acute 
and chronic liver infections in human [1]. From the 
epidemiological perspective, the highest prevalence 
of CHB is reported in Africa and Asia [2]. According to 
Baseline Health Research, the prevalence of Hepatitis 
B in Indonesia increased from 0.2% in 2013 to 0.4% in 
2018 [3]. Although the coverage for early detection and 
immunization for hepatitis B has always reached the 
target until 2017 [4], Indonesia is still categorized as a 
moderate-to-highly endemic region for HBV infection [5]. 
The majority cases of Hepatitis B can progress to 
chronic liver disease, with the chronicity depends on 
the time exposure to hepatitis B virus (HBV) [6]. If left 
untreated, the disease can lead to fatal complications, 
including cirrhosis, liver failure, and hepatocellular 
carcinoma [6], [7], [8]. In fact, after 5 years of suffering 
from CHB, the risk of developing hepatocellular 
carcinoma increases up to 17% in Eastern countries 
compared to 10% in western countries. The 5-year 
survival rate for patients with decompensated liver 
cirrhosis due to HBV is 17–35% [9]. Thus, a series of 
good management is needed to prevent the progression 
and complications of Hepatitis B infection.
There are many different treatment options 
available. Treatments that are used in CHB management 
are peginterferon-alpha, lamivudine (LMV), adefovir 
(ADV), telbivudine, entecavir (ETV), and tenofovir 
(TDF) [7]. Several parameters are used to monitor CHB 
progression such as serum alanine aminotransferase 
(ALT) level, HBV DNA level, antigens specific to HBV, 
and histopathological examination [1], [7], [10], [11]. 
Viral suppression, ALT normalization, absence of viral 
resistance, HBeAg loss, HBsAg seroconversion, and liver 
histology improvement are the short-term goals regarding 
with CHB infection [1]. Furthermore, the long-term aims 
of management of CHB are to improve survival rate 
and to prevent complications [2], [9], [10]. Moreover, the 
treatment for this condition may need to be lifelong, thus 
the drugs used must be both efficacious and safe [11].
TDF is one of the nucleotide analogue drug that is 
used as the first-line treatment of CHB [8], [12, [13], [14]. 
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This pharmacological agent is recommended for naive 
CHB patients but can also be administered to patients 
with previous treatment failure [8], [9]. Many literatures 
stated that TDF has good efficacy and safety. However, 
several adverse events have been reported such as 
renal toxicity and bone demineralization [6], [7], [15]. 
Other disadvantages of nucleotide analogs in treating 
CHB are indefinite duration of treatment, risk of 
developing resistance, and less HBeAg and HBsAg 
conversions [9], [15]. Only one single-centered study was 
found that has discussed the efficacy and side effects of 
tenofovir in Indonesia [16,17,18]. Moreover, Indonesia 
is a country with a diversity of cultures, religions, and 
races so that the research on the efficacy of TDF against 
CHB infection regarding that heterogeneity is in need. 
Unfortunately, limited studies were found regarding the 
efficacy of tenofovir in dealing with CHB in Indonesia. Our 
study aimed to determine the efficacy of 24-week TDF 
treatment in naive CHB subjects in Medan, Indonesia.
Methods
A retrospective study was conducted in Haji 
Adam Malik Hospital Medan, Indonesia between January 
and December 2019. The inclusion criteria were patients 
aged 18 years or older, who were diagnosed with CHB. 
Patients were excluded if they had underlying liver damage 
other than CHB such as liver cirrhosis, hepatocellular 
carcinoma, co-infection with others hepatitis virus, renal 
disease, autoimmune disease, and immunodeficiency 
disease. Consecutive sampling method was used for 
this study and subjects should have received 300 mg of 
TDF daily for a minimum 24 weeks. Moreover, subjects 
were divided into 2 groups based on the HBeAg positivity. 
Demographic and clinical characteristics were gathered 
from each subject’s medical record along with CHB 
disease progression parameters (serum ALT, HBV 
DNA level, HBeAg, and HBsAg) after 24 weeks of TDF 
treatment. Data analysis was conducted using McNemar’s 
test for the categorical dependent variable, for instance, 
seroconversion of HBeAg. Continuous variables (serum 
ALT, HBV DNA level) were presented as mean ± 
standard deviation and were compared using the paired 
t-test. p < 0.05 was considered statistically significant. 
This study was approved by the Health Research Ethical 
Committee, Medical School, Universitas Sumatera Utara.
Results
A total of 120 subjects were enrolled in this 
study and almost equally divided into two groups based 
on the HBeAg positivity. In this study, male subjects 
were mostly found in HBeAg positive (58.3%) and 
HBeAg negative (61.7%) groups. Mean age and body 
mass index of subjects were higher in HBeAg negative 
compared to HBeAg positive group. On the other hand, 
serum ALT and HBV DNA levels were higher in subjects 
in the HBeAg positive group (Table 1).
Table 1: Baseline characteristics of the subjects
Characteristics HBeAg positive
(n = 52)
HBeAg negative
(n = 68)
Mean age, years 46.5 ± 10.36 48.6 ± 10.67
Sex, n (%)
Male
Female
70 (58.3%)
50 (41.7%)
74 (61.7%)
46 (38.3%)
Mean body mass index, kg/m2 22.2 ± 3.22 23.3 ± 2.98
Family history of hepatitis B, n (%) 89 (74.2%) 86 (71.7%)
Mean serum ALT (*), IU/L 128.1 ± 96.75 112.4 ± 89.31
Mean HBV DNA (**) serum, log10 IU/mL 7.06 ± 1.24 6.21 ± 1.32
Family history of hepatitis B, n (%) 89 (74.2%) 86 (71.7%)
*ALT: Alanine aminotransferase, **HBV DNA: Hepatitis B virus deoxyribonucleic acid
Administration of TDF for 24 weeks showed 
good efficacy both in HBeAg negative and positive 
groups. In point of fact, serum ALT normalization 
was achieved in 71.7% subjects with HBeAg positive 
(p < 0.001) and in 75% subjects with HBeAg negative 
(p < 0.001). A similar proportion was observed in 
subjects with undetectable serum HBV DNA in both 
groups. The decline of serum HBV DNA was lower in 
HBeAg positive group (6.08 log10 IU/mL; p < 0.001) 
in compared with those in HBeAg negative group 
(5.02 log10 IU/mL; (p < 0.001). HBeAg loss was achieved 
by 10.8% of subjects with HBeAg positive (p < 0.001) 
although no subjects in this study showed HBsAg loss 
(Table 2).
Table 2: Efficacy of 24-week administration of TDF in CHB 
subjects
Parameters HBeAg positive 
n = 52
p value HBeAg negative 
n = 68
p value
Serum ALT (*) 
normalization, n (%)
86 (71.7%) p < 0.001 90 (75.0%) p < 0.001
HBeAg loss, n (%) 13 (10.8%) p < 0.001 N/A -
HBsAg loss, n (%) 0 (0.0%) - 0 (0.0%) -
Undetectable 
serum HBV DNA 
(**), n (%)
81 (67.5%) p < 0.001 83 (69.2%) p < 0.001
Mean decline in 
serum HBV DNA 
(**), log10 IU/mL
-6.08±1.23 - −5.02±1.12 -
*ALT: Alanine aminotransferase, **HBV DNA: Hepatitis B virus deoxyribonucleic acid
Discussion
There are 240–400 million cases of CHB all 
over the world which is endemic in sub-Saharan Africa 
and Asia-Pacific region due to the high rate of perinatally 
and early childhood infection [2], [19], [20], [21]. In the 
western world, CHB is mainly caused by unhealthy 
lifestyle such as high-risk sexual behavior and 
injection drug use [1], [2], [18], [19]. We found that 
both groups had a male population is more affected 
than women. This result is not much different from 
other countries in Asia, such as China, stated that 
males are more commonly affected by CHB compared 
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to females [8], [9], [10], [13]. The mean age of HBV 
positive patients under TDF treatment was 46.5± 10.36 
years and 48.6  ± 10.67 years in HBeAg positive and 
HBeAg negative, respectively. According to literature, 
mean age of patients with CHB ranges from 30.3 to 
40.4 years [10]. Other study reported a higher mean 
which was 51.3 years [16]. Shi et al. reported a younger 
range of age which was 33.7 to 35.1 years [10].
TDF is a nucleotide analogue which acts by 
inhibiting HBV DNA polymerase reverse transcriptase 
enzyme, terminating viral DNA chain elongation, and 
stopping viral genome replication [9], [12], [13], [20]. 
Initially, TDF is used to treat human immunodeficiency 
virus (HIV) infection [7]. As stated above, our objective 
of the study is to examine the efficacy of TDF agent in 
treating CHB infection. Knowing that TDF is considered 
highly effective in treating naïve CHB, we chose the 
naive CHB patients for being the study population in 
this research. All of them received TDF monotherapy 
for 24 weeks and the efficacy of CHB treatment is 
followed up with serum ALT, HBV DNA levels, and the 
seroconversion of HBeAg status.
A study conducted by Ormeci et al. showed 
that after a mean follows up of 30.31 months, 86.5% 
patients with CHB experienced HBV DNA negativity and 
the other 71.3% had normal alanine aminotransferase 
level. However, only 19.6% patients showed HBeAg 
seroconversion in the study [9]. Lovett et al. found that TDF 
might suppress viral load effectively. After administration 
of the drug for >3 months, virological suppression was 
increased by time after TDF administration from 71% 
at 12 months to 96.7% at 36 months after treatment. 
Indeed, the efficacy was influenced by baseline HBV 
DNA level and HBeAg positive status. The study also 
found that efficacy was not different between naïve and 
previously treated patients. TDF was also well tolerated 
by the patients in the study [7]. TDF administration for 
48 weeks would result in 92.9% virologic response in 
naïve CHB patients. The rest showed a partial virologic 
response and it was suggested due to the high level of 
serum HBV DNA. Continuous treatment with TDF may 
increase the rate of virologic response [17].
A meta-analysis showed that TDF had the 
second-highest HBeAg seroconversion property in 
patients with CHB. It was only surpassed by telbivudine. 
This condition was achieved by 52 weeks of treatment. 
However, HBeAg seroconversion induced by nucleotide 
analogs is temporary; therefore, it requires long-term 
treatment [20]. A study from Turkey had shown that 
no subjects developed resistance toward TDF after 
12 months of treatment. In addition, 8.3% subjects had 
HBeAg seroconversion at 9th month, 80% subjects with 
positive HBeAg had undetectable HBV DNA, and 91.2% 
subjects with negative HBeAg had undetectable HBV 
DNA. At 12th month of treatment, ALT normalization was 
observed in 80.4% subjects. HBsAg seroconversion 
was very low in this study (0.85%) [1]. Other study stated 
that the management of CHB with 96 weeks of TDF 
administration had good efficacy in 95% patients. The 
study involved naïve and previously-treated patients 
from the Chinese population. Nephrotoxicity had been 
reported, but it was recovered at 96th week without TDF 
withdrawal [17].
Those results were similar to the results from 
our study (Table 2). TDF had good efficacy in managing 
patients with CHB even with a shorter treatment period. 
In our study, it showed that more than 70% of the 
patients achieved ALT normalization, respectively, in 
HBeAg positive and HBeAg negative population. HBeAg 
seroconversion was reached in 10.8% population after 
receiving TDF for 24 weeks. More than 65% subjects 
had their serum HBV DNA undetected at the 24th week 
of therapy. However, in our study, serum HBeAg loss 
rate was low and no subjects showed serum HBsAg 
loss. The reason for the lower rate of HBeAg loss at the 
end of 24-week treatment in our study can be explained 
by the limited number of patients and longer treatment 
period is expected to improve TDF efficacy in patients 
with CHB.
In accordance with our study, previous data 
also showed that HBsAg loss was rarely achieved 
by administration of TDF alone in patients with CHB. 
A study done by Ahn et al. demonstrated that the 
combination of TDF and pegylated interferon (PEG-
IFN) had significant higher efficacy compared to TDF or 
PEG-IFN alone. They evaluated the efficacy based on 
seroconversion of HBsAg and HBeAg [3]. Other study 
reported that TDF monotherapy had lower virological 
response compared to TDF-based combination therapy. 
Longer treatment was associated with higher HBeAg 
and HBsAg loss or seroconversion [2]. Therefore, 
combination therapy with drugs from other classes is 
suggested although longer-duration studies conducted 
by Liang et al. [13] and Chen et al. [15] reported that 
both TDF monotherapy and TDF-based combination 
therapy possessed good efficacy.
Administration of TDF in patients with CHB 
who had received other nucleoside analogs previously 
also showed good efficacy with reference to the serum 
HBV DNA loss. A total of 93% patients who previously 
received lamivudine had no HBV DNA detected at 
18 months after TDF treatment. A similar condition was 
observed in 86% of patients who previously received 
lamivudine and entecavir [8]. Less efficacy of TDF was 
reported in subjects with human immunodeficiency virus 
(HIV) and HBV co-infection. In that particular population, 
TDF-containing regimens administration resulted in 
24.9% HBeAg loss, 23.7% HBeAg conversion, 7.3% 
HBsAg loss, and 5.5% HBsAg conversion. The low 
rates were due to liver involvement in HIV infection and 
hepatotoxicity of antiretroviral drugs [14].
Several factors influence the efficacy of CHB 
treatment. As a long-term, even life-long treatment 
is usually applied for patients with CHB, patient’s 
compliance is important in achieving disease 
improvement [6]. Difference in subjects’ response 
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to treatment may be caused by a difference in the 
genotype of HBV. In Caucasians, for example, the 
most common genotypes are A and D compared to 
genotype B and C in the Chinese population [10]. 
Good efficacy of treatment is affected by HBeAg-
negative status, lower baseline HBV DNA level, and 
lower HBsAg level [2], [19]. In addition, HBV virion 
is difficult to clear from hepatocytes because of the 
presence of covalently closed circular DNA in the 
host’s cell nucleus [12], [16].
The strength from our study was that we 
conducted the research in Medan, which is one of 
the urban cities in Indonesia with diverse races. On 
the contrary, this study had several limitations. Its 
retrospective design prevented us from evaluating 
subjects’ treatment compliance. The evaluation of 
treatment response did not involve a histopathologic 
examination. We also did not compare the efficacy of 
TDF monotherapy and TDF-based combination therapy, 
the sociodemographic parameters such as age, sex, 
as well as the efficacy of TDF in naïve and previously 
treated subjects with CHB. Thus, we recommend future 
researchers to conduct further analysis on this subject 
matter. In conclusion, administration of TDF for 24 
weeks has good efficacy for patients with CHB.
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